Prevalence of new-onset migraine in patients with idiopathic intracranial hypertension in comparison to the general population
Background: Idiopathic intracranial hypertension (IIH) encompasses patients with elevated intracranial pressure (ICP). Generally, it is difficult to make a differential diagnosis between IIH and co-existing migraine headaches. Thus, this article intends to estimate the prevalence of migraine in patients with IIH and explain the occurrence of new-onset migraine after the diagnosis of IIH.
Methods: The case group included 108 patients with IIH referred to the neurology wards of three university hospitals. A random sample of controls (n = 103) were recruited from patients hospitalized in the surgery and orthopedics ward. A checklist for migraine diagnosis was filled out. Cerebrospinal fluid (CSF) pressure and presence or absence of papilloedema (PE) in the patients and any necessary data were also recorded from the inpatient medical documents. All statistical analyses were done by SPSS software.
Results: There were 70 (64.80%) and 22 (21.40%) migraineurs in the case and control groups, respectively, and the difference was found to be significant (P < 0.001). In 26 (37.14%) migraine cases in the IIH group, the disorder was diagnosed after developing IIH. Also, there was a past medical history of having migraine in 44 (62.85%) migraineurs. In the fully adjusted regression models, the odds of being affected by migraine in patients with IIH was 6.17 times greater than the controls [odds ratio (OR) = 7.15, 95% confidence interval (CI) = 3.56-14.36, P < 0.010]. The patients’ mean CSF opening pressure was 32.10 ± 1.03 cmH2O and 93 (81.60%) subjects were found to have PE.
Conclusion: It was demonstrated that subjects with IIH might have about a 6-time higher likelihood of developing migraine headache than the general population. These considerations can help prevent misdiagnosis of migraine headache as the recurrence of IIH or uncontrolled IIH and subsequent inappropriate management.
2. Friedman DI, Rausch EA. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology 2002; 58(10): 1551-3.
3. Kleinschmidt JJ, Digre KB, Hanover R. Idiopathic intracranial hypertension: Relationship to depression, anxiety, and quality of life. Neurology 2000; 54(2): 319-24.
4. McGeeney BE, Friedman DI. Pseudotumor cerebri pathophysiology. Headache 2014; 54(3): 445-58.
5. Jensen RH, Radojicic A, Yri H. The diagnosis and management of idiopathic intracranial hypertension and the associated headache. Ther Adv Neurol Disord 2016; 9(4): 317-26.
6. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 (Pt 1A): 155-80.
7. Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol 1988; 45(8): 875-7.
8. Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. Surv Ophthalmol 2007; 52(6): 597-617.
9. Wall M. Update on Idiopathic Intracranial Hypertension. Neurol Clin 2017; 35(1): 45-57.
10. Bruce BB, Kedar S, Van Stavern GP, Monaghan D, Acierno MD, Braswell RA, et al. Idiopathic intracranial hypertension in men. Neurology 2009; 72(4): 304-9.
11. Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): A case-control study. Neurology 1991; 41: 2(Pt 1): 239-44.
12. Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri). Curr Neurol Neurosci Rep 2008; 8(2): 87-93.
13. Friedman DI. Pseudotumor cerebri. Neurol Clin 2004; 22(1): 99-131, vi.
14. Henouda AS, Metti F, Nouri M. Blindness in idiopathic intracranial hypertension. Journal Francais D Ophtalmologie 2007; 30: 588.
15. Mallery RM, Friedman DI, Liu GT. Headache and the pseudotumor cerebri syndrome. Curr Pain Headache Rep 2014; 18(9): 446.
16. Bono F, Messina D, Giliberto C, Cristiano D, Broussard G, Fera F, et al. Bilateral transverse sinus stenosis predicts IIH without papilledema in patients with migraine. Neurology 2006; 67(3): 419-23.
17. Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. The idiopathic intracranial hypertension treatment trial: Clinical profile at baseline. JAMA Neurol 2014; 71(6): 693-701.
18. Sorensen PS, Corbett JJ. High cerebral fluid pressure. In: Olesen J, Tfelt-Hansen P, Welch MA, Editors. The headaches. Philadelphia, PA: Lippincott Williams & Wilkins; 2000. p. 823-30.
19. MacGregor EA. Migraine. Ann Intern Med 2017; 166(7): ITC49-ITC64.
20. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review. Cephalalgia 2011; 31(7): 837-50.
21. Harandi SA, Togha M, Sadatnaseri A, Hosseini SH, Jahromi SR. Cardiovascular risk factors and migraine without aura: A case-control study. Iran J Neurol 2013; 12(3): 98-101.
22. Martami F, Ghorbani Z, Abolhasani M, Togha M, Meysamie A, Sharifi A, et al. Comorbidity of gastrointestinal disorders, migraine, and tension-type headache: A cross-sectional study in Iran. Neurol Sci 2018; 39(1): 63-70.
23. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: Will health politicians now take notice? J Headache Pain 2018; 19(1): 17.
24. Lima AM, Sapienza GB, Giraud Vde O, Fragoso YD. Odors as triggering and worsening factors for migraine in men. Arq Neuropsiquiatr 2011; 69(2B): 324-7.
25. Rasmussen BK. Epidemiology of headache. Cephalalgia 2001; 21(7): 774-7.
26. Farhadi Z, Alidoost S, Behzadifar M, Mohammadibakhsh R, Khodadadi N, Sepehrian R, et al. The prevalence of migraine in Iran: A systematic review and meta-analysis. Iran Red Crescent Med J 2016; 18(10): e40061.
27. Ramadan NM. Intracranial hypertension and migraine. Cephalalgia 1993; 13(3): 210-1.
28. Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology 1996; 46(5): 1226-30.
29. The international classification of headache disorders, 3rd edition (Beta version). Cephalalgia 2013; 33(9): 629-808.
30. Sina F, Razmeh S, Habibzadeh N, Zavari A, Nabovvati M. Migraine headache in patients with idiopathic intracranial hypertension. Neurol Int 2017; 9(3): 7280.
31. Amico D, Curone M, Ciasca P, Cammarata G, Melzi L, Bussone G, et al. Headache prevalence and clinical features in patients with idiopathic intracranial hypertension (IIH). Neurol Sci 2013; 34(Suppl 1): S147-S149.
32. Subramaniam S, Fletcher WA. Obesity and weight loss in idiopathic intracranial hypertension: A narrative review. J Neuroophthalmol 2017; 37(2): 197-205.
33. D'Amico D, Curone M, Erbetta A, Farago' G, Bianchi-Marzoli S, Ciasca P, et al. Intracranial idiopathic hypertension: 1-year follow-up study. Neurol Sci 2014; 35(Suppl 1): 177-9.
34. Razeghi JS, Abolhasani M, Ghorbani Z, Sadre-Jahani S, Alizadeh Z, Talebpour M, et al. Bariatric surgery promising in migraine control: A controlled trial on weight loss and its effect on migraine headache. Obes Surg 2018; 28(1): 87-96.
35. Jahromi SR, Abolhasani M, Meysamie A, Togha M. The effect of body fat mass and fat free mass on migraine headache. Iran J Neurol 2013; 12(1): 23-7.
36. De Simone R, Ranieri A. The role of intracranial hypertension in the chronification of migraine. Neurol Sci 2015; 36(Suppl 1): 23-8.
37. van Alphen HA. Migraine, a result of increased CSF pressure: A new pathophysiological concept (preliminary report). Neurosurg Rev 1986; 9(1-2): 121-4.
38. Digre K. Papilledema and idiopathic intracranial hypertension. In: Kidd DP, Newman NJ, Biousse VR, Editors. Blue books of neurology neuro-ophthalmology. Oxford, UK: Butterworth-Heinemann; 2008. p. 280-311.
39. Lipton HL, Michelson PE. Pseudotumor cerebri syndrome without papilledema. JAMA 1972; 220(12): 1591-2.
40. Marcelis J, Silberstein SD. Idiopathic intracranial hypertension without papilledema. Arch Neurol 1991; 48(4): 392-9.
41. Digre KB, Nakamoto BK, Warner JE, Langeberg WJ, Baggaley SK, Katz BJ. A comparison of idiopathic intracranial hypertension with and without papilledema. Headache 2009; 49(2): 185-93.
42. Torbey MT, Geocadin RG, Razumovsky AY, Rigamonti D, Williams MA. Utility of CSF pressure monitoring to identify idiopathic intracranial hypertension without papilledema in patients with chronic daily headache. Cephalalgia 2004; 24(6): 495-502.
43. Vieira DS, Masruha MR, Goncalves AL, Zukerman E, Senne Soares CA, Naffah-Mazzacoratti MG, et al. Idiopathic intracranial hypertension with and without papilloedema in a consecutive series of patients with chronic migraine. Cephalalgia 2008; 28(6): 609-13.